Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.
Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M. Marcellin P, et al. Among authors: roberts sk. Expert Opin Drug Saf. 2012 Nov;11(6):901-9. doi: 10.1517/14740338.2012.721927. Epub 2012 Sep 4. Expert Opin Drug Saf. 2012. PMID: 22943161
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ; CHARIOT Study Group. Cheng WS, et al. Among authors: roberts sk. J Hepatol. 2010 Oct;53(4):616-23. doi: 10.1016/j.jhep.2010.04.024. Epub 2010 Jun 16. J Hepatol. 2010. PMID: 20619475 Clinical Trial.
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; CHARIOT Study Group. Sievert W, et al. Among authors: roberts sk. Hepatology. 2011 Apr;53(4):1109-17. doi: 10.1002/hep.24180. Hepatology. 2011. PMID: 21480317 Clinical Trial.
Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies.
Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J; Australian Liver Association Clinical Research Network. Roberts SK, et al. J Gastroenterol Hepatol. 2014 Jan;29(1):179-84. doi: 10.1111/jgh.12424. J Gastroenterol Hepatol. 2014. PMID: 24219707
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, McCaughan GW, Crawford DH, Cheng WS, Weltman MD, Bonanzinga S, Visvanathan K, Sundararajan V, Desmond PV, Bowden DS, Matthews GV, Thompson AJ; CHARIOT Study Group. Holmes JA, et al. Among authors: roberts sk. Hepatology. 2014 Jun;59(6):2152-60. doi: 10.1002/hep.27022. Epub 2014 Apr 25. Hepatology. 2014. PMID: 24449403
306 results